Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine

Journal of Medical Toxicology

Volumn 5, Issue 1, 2009, Pages 27-31

  Morris, Enasio ^a   Green, Digby ^a   Graudins, Andis ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Chlorpromazine; Deliberate self poisoning; Drug toxicity; Neuroleptic malignant syndrome; Olanzapine

Indexed keywords

BROMOCRIPTINE; CHLORPROMAZINE; ESCITALOPRAM; MIDAZOLAM; OLANZAPINE; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; DOPAMINE RECEPTOR STIMULATING AGENT; HYPNOTIC SEDATIVE AGENT; NEUROLEPTIC AGENT;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; ASPIRATION PNEUMONIA; ATAXIA; BLOOD PRESSURE; BREATHING RATE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; COOLING; DROWSINESS; DRUG INTOXICATION; DRUG OVERDOSE; ELECTROCARDIOGRAM; ELECTROCONVULSIVE THERAPY; ELECTROENCEPHALOGRAM; EMERGENCY WARD; FEMALE; FEVER; HEART RATE; HUMAN; INGESTION; LUMBAR PUNCTURE; MENTAL HEALTH; MUSCLE HYPERTONIA; NEUROLEPTIC MALIGNANT SYNDROME; NEUROLOGIC EXAMINATION; NEUROMUSCULAR DISEASE; RIGIDITY; TACHYCARDIA; THORAX RADIOGRAPHY; CRYOANESTHESIA; INTOXICATION; INTRAVENOUS DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BROMOCRIPTINE; CHLORPROMAZINE; CITALOPRAM; COMBINED MODALITY THERAPY; DOPAMINE AGONISTS; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; HYPOTHERMIA, INDUCED; INFUSIONS, INTRAVENOUS; MIDAZOLAM; NEUROLEPTIC MALIGNANT SYNDROME; OVERDOSE; RESPIRATION, ARTIFICIAL; TREATMENT OUTCOME;

EID: 65249114126     PISSN: 15569039     EISSN: 19376995     Source Type: Journal    
DOI: 10.1007/BF03160978     Document Type: Article

References (22)

1. Goveas JS, Hermida A. Olanzapine induced typical neuroleptic malignant syndrome. J Clin Psychopharmacol 2003; 23(1):101-102.
2. Nielsen J, Bruhn AM. Atypical neuroleptic malignant syndrome caused by olanzapine. Acta Psychiatr Scand 2005;112(2): 238-240.
3. Hall KL, Taylor WH, Ware MR. Neuroleptic malignant syndrome due to olanzapine. Psychopharmacol Bull 2001; 35(3):49-54.
4. Kontaxakis VP, Havaki-Kontaxaki BJ, Christodoulou NG, et al. Olanzapine-associated neuroleptic malignant syndrome. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26(5):897-902.
5. Sierra-Biddle D, Herran A, Diez-Aja S, et al. Neuroleptic malignant syndrome and olanzapine. J Clin Psychopharmacol 2000;20(6):704-705.
6. Morgan M, Hackett LP, Isbister GK. Olanzapine overdose: A series of analytically confirmed cases. Int Clin Psychopharmacol 2007;22(3):183-186.
7. Cohen LG, Fatalo A, Thompson BT, et al. Olanzapine overdose with serum concentrations. Ann Emerg Med 1999; 34(2):275-278.
8. Goveas JS, Hermida A. Olanzapine induced typical neuroleptic malignant syndrome. J Clin Psychopharmacol 2003; 23(1):101-102.
9. Nielsen J, Bruhn AM. Atypical neuroleptic malignant syndrome caused by olanzapine. Acta Psychiatr Scand 2005;112(3): 238-240; discussion 40.
10. Philibert RA, Adam LA, Frank FM, et al. Olanzapine usage associated with neuroleptic malignant syndrome. Psychosomatics 2001;42(6):528-529.
11. Gelenberg AJ, Bellinghausen B, Wojcik JD, et al. A prospective survey of neuroleptic malignant syndrome in a short term psychiatry hospital. Am J Psychiatry 1988;145: 517-518.
12. Hansan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome. Am J Psychiatry 1998;155(8): 1113-1116.
13. Kontaxakis VP, Havaki-Kontaxaki BJ, Christodoulou NG, et al. Olanzapine-associated neuroleptic malignant syndrome: Is there an overlap with the serotonin syndrome? Ann Gen Hosp Psychiatry 2003;2(1):10.
14. Pope HGJ, Keck PEJ, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in large psychiatric hospital. Am J Psychiatry 1986;143:1227-1233.
15. Sachdev P, Mason C, Hadzi-Pavlovic D. Case control study of neuroleptic malignant syndrome. Am J Psychiatry 1997; 154:1156-1158.
16. Dunkley EJ, Isbister GK, Sibbritt D, et al. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 2003;96: 635-642.
17. Keck PE Jr, Pope HG Jr, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome: a prospective study. Am J Psychiatry 1987;144:1344-1346.
18. Stanfield SC, Privette T. Neuroleptic malignant syndrome associated with olanzapine therapy: a case report. J Emerg Med 2000;19:355-357.
19. Apple JE, Van Hauer G. Neuroleptic malignant syndrome associated with olanzapine therapy. Psychosomatics 1999;40(3): 267-277.
20. Ozer F, Meral H, Ayadin B, et al. Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndrome. J ECT 2005;21(2):125-127.
21. Scheftner WA, Shulman RB. Treatment choice in neuroleptic malignant syndrome. Convuls Ther 1992;8(4): 267-279.
22. Rotheke S, Bush D. Neuropsychological sequelae of Neuroleptic Malignant Syndrome. Biol Psychiatry 1986;21: 838-841.